Zabofloxacin, formerly known as DW-224; DW-224a; PB-101, is DNA topoisomerase IV inhibitor potentially for the treatment of chronic obstructive pulmonary disease. Zabofloxacin shows activity for multidrug-resistant infections due to Gram-positive bacteria. Zabofloxacin has a broad spectrum of antimicrobial activity, which is especially potent against Gram-positive bacteria. References: Kim T, Park SJ, Chong YP, Park KH, Lee YM, Hong HL, Kim HS, Kim ES, Lee S, Choi DR, Kim SH, Jeong JY, Lee SO, Choi SH, Woo JH, Kim YS. Fluoroquinolone resistance of Streptococcus pneumoniae isolates causing invasive disease: special focus on zabofloxacin. Diagn Microbiol Infect Dis. 2016 Jul 22. pii: S0732-8893(16)30227-9. doi: 10.1016/j.diagmicrobio.2016.07.019. [Epub ahead of print] PubMed PMID: 27498611.

纯度：≥98%

CAS：623574-00-5